Our reports

Reports referring to our work

Our scientific publications

Our Reports

Värdebaserad uppföljning av bröstcancervård

En förstudie inom Sveus i samverkan med Regionalt Cancercentrum Stockholm-Gotland

Publication year: 2016
Authors: Abc…
ISBN: 123…
Format: PDF
Number of pages: xx
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Performance monitoring of stroke care

Report from development of new monitoring system for stroke care in Sweden

Publication year: 2015
Authors: Sveus stroke expert group
ISBN: 1 978-91-982603-0-4
Format: PDF
Number of pages: 152
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Performance monitoring of childbirth care

Report from development of new monitoring system for child birth care in Sweden

Publication year: 2015
Authors: Sveus childbirth expert group
ISBN: 2 978-91-982603-1-1
Format: PDF
Number of pages: 122
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Performance monitoring of diabetes care

Report from development of new monitoring system for diabetes care in Sweden

Publication year: 2015
Authors: Sveus diabetes expert group
ISBN: 3 978-91-982603-2-8
Format: PDF
Number of pages: 154
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Performance monitoring for spine surgery

Report from development of new monitoring system for spine surgery in Sweden

Publication year: 2015
Authors: Sveus diabetes expert group
ISBN: 4 978-91-982603-3-5
Format: PDF
Number of pages: 137
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Performance monitoring for bariatric surgery

Report from development of new monitoring system for bariatric surgery in Sweden

Publication year: 2015
Authors: Sveus bariatric surgery expert group
ISBN: 5 978-91-982603-4-2
Format: PDF
Number of pages: 135
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Performance monitoring for hip and knee replacement

Report from development of new monitoring system for arthroplasty surgery in Sweden

Publication year: 2015
Authors: Sveus arthroplasty surgery expert group
ISBN: 6 978-91-982603-5-9
Format: PDF
Number of pages: 121
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Reimbursement in Health Care; models, effects, recommendations

SNS report 

Publication year: 2014
Author: Peter Lindgren
ISBN: 978-91-86949-56-3
Format: PDF
Number of pages: 60
Language: Swedish
Price (incl. VAT): 0 SEK

View PDF

Reports Referring to Our Work

Better ways to pay for health care

OECD Health Policy Studies 

Publication year: 2016
Author: Divya Srivastava et. al.
ISBN: 987-92-64-25821-1
Format: PDF
Number of pages: 170
Language: English
Price (incl. VAT): 0 SEK

View PDF

Our Scientific Publications

Mesterton J, Lindgren P, Ekenberg Abreu A, Ladfors L, Lilja M, Saltvedt S och Amer-Wahlin I. Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study. BMC Pregnancy Childbirth. 2016;16(1):125.

Marques A, Lourenco O, Ortsater G, Borgstrom F, Kanis JA och da Silva JA. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX((R)) in Portugal. Calcif Tissue Int. 2016 Aug;99(2):131-41.

Jurisson M, Pisarev H, Kanis J, Borgstrom F, Svedbom A, Kallikorm R, Lember M och Uuskula A. Quality of life, resource use, and costs related to hip fracture in Estonia. Osteoporos Int. 2016 Aug;27(8):2555-66.

Hallberg S, Gandra SR, Fox KM, Mesterton J, Banefelt J, Johansson G, Levin LA och Sobocki P. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data. Eur J Health Econ. 2016 Jun;17(5):591-601.

Hallberg S, Banefelt J, Fox KM, Mesterton J, Johansson G, Levin LA, Sobocki P och Gandra SR. Lipid-lowering treatment patterns in patients with new cardiovascular events – estimates from population-based register data in Sweden. Int J Clin Pract. 2016 Mar;70(3):222-8.

Forsth P, Olafsson G, Carlsson T, Frost A, Borgstrom F, Fritzell P, Ohagen P, Michaelsson K och Sanden B. A Randomized, Controlled Trial of Fusion Surgery for Lumbar Spinal Stenosis. N Engl J Med. 2016 Apr 14;374(15):1413-23.

Eklund O, Afzal F, Borgstrom F, Flavin J, Ternouth A, Ojanguren ME, Crespo C och Baldwin M. Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK. Clinicoecon Outcomes Res. 2016;8:243-52.

Bergkvist C, Berglund M, Glynn A, Julin B, Wolk A och Akesson A. Dietary exposure to polychlorinated biphenyls and risk of myocardial infarction in men – A population-based prospective cohort study. Environ Int. 2016 Mar;88:9-14.

Ali I, Julin B, Glynn A, Högberg J, Berglund M, Johansson J-E, Andersson S-O, Andrén O, Giovannucci E, Wolk A, Stenius U och Åkesson A. Exposure to Polychlorinated Biphenyls and Prostate Cancer: Population-based Prospective Cohort and Experimental Studies. Carcinogenesis. 2016;In print.

Teitsson S, Bobula J, Hawes C, Moffatt M, Ohna A och Borgstrom F. Cost-Effectiveness of Conjugated Estrogens/Bazedoxifene for the Treatment of Vasomotor Symptoms in the United States. Value Health. 2015 Nov;18(7):A736.

Strom O, Landfeldt E och Garellick G. Residual effect after oral bisphosphonate treatment and healthy adherer effects–the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2015 Jan;26(1):315-25.

Pyko A, Eriksson C, Oftedal B, Hilding A, Ostenson CG, Krog NH, Julin B, Aasvang GM och Pershagen G. Exposure to traffic noise and markers of obesity. Occup Environ Med. 2015 Aug;72(8):594-601.

Olafsson G, Jonsson E, Fritzell P, Hagg O och Borgstrom F. Burden of Spinal Diseases: Results From Register Study In Sweden. Value Health. 2015 Nov;18(7):A642.

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M och Strom O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015 Oct;26(10):2401-11.

Julin B, Shui IM, Prescott J, Giovannucci EL och De Vivo I. Plasma vitamin D biomarkers and leukocyte telomere length in men. Eur J Nutr. 2015 Nov 11.

Julin B, Shui I, Heaphy CM, Joshu CE, Meeker AK, Giovannucci E, De Vivo I och Platz EA. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. Br J Cancer. 2015 Feb 17;112(4):769-76.

Jonsson E, Olafsson G, Fritzell P, Hagg O och Borgstrom F. Productivity Loss Due to Low Back Pain: Results from Swedish Registers. Value Health. 2015 Nov;18(7):A649.

Jonsson E, Eriksson D, Akesson K, Ljunggren O, Salomonsson S, Borgstrom F och Strom O. Swedish osteoporosis care. Arch Osteoporos. 2015;10:222.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortere R, Cenci MA och Newman-Tancredi A. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Exp Neurol. 2015 Sep;271:335-50.

Iderberg H, McCreary AC, Varney MA, Cenci MA och Newman-Tancredi A. Activity of serotonin 5-HT(1A) receptor ‘biased agonists’ in rat models of Parkinson’s disease and L-DOPA-induced dyskinesia. Neuropharmacology. 2015 Jun;93:52-67.

Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK och Cenci MA. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson’s disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology. 2015 Aug;95:121-9.

Henry N, Schlueter M, Lowin J, Lekander I , Filonenko A, Trussell J och Skjeldestad FE. Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception. J Fam Plann Reprod Health Care. 2015 Apr;41(2):109-15.

Henry N, Hawes C, Lowin J, Lekander I , Filonenko A och Kallner HK. Cost-effectiveness analysis of a low-dose contraceptive levonorgestrel intrauterine system in Sweden. Acta Obstet Gynecol Scand. 2015 Aug;94(8):884-90.

Francardo V, Iderberg H, Lindgren HS och Cenci AM. Rodent Models of Treatment-Related Complications in Parkinson’s disease. In: M L, editor. Movement Disorders: Genetics and Models. 2nd ed. Oxford U K: Elsevier; 2015. p. 373-86.

Eklund O, Afzal F, Borgstrom F, Ojanguren ME, Crespo C och Baldwin M. Cost-Effectiveness Of Tiotropium Vs Glycopyrronium In Moderate To Very Severe Copd In Spain. Value Health. 2015 Nov;18(7):A501.

Eklund O, Afzal F och Borgstrom F. Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden. Cost Eff Resour Alloc. 2015;13:13.

Borgstrom F, Beall DP, Berven S, Boonen S, Christie S, Kallmes DF, Kanis JA, Olafsson G, Singer AJ och Akesson K. Health economic aspects of vertebral augmentation procedures. Osteoporos Int. 2015 Apr;26(4):1239-49.

Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, Levin LA, Sobocki P och Gandra SR. Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden. Eur J Health Econ. 2015 Nov 25.

Abimanyi-Ochom J, Watts JJ, Borgstrom F, Nicholson GC, Shore-Lorenti C, Stuart AL, Zhang Y, Iuliano S, Seeman E, Prince R, March L, Cross M, Winzenberg T, Laslett LL, Duque G, Ebeling PR och Sanders KM. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). Osteoporos Int. 2015 Jun;26(6):1781-90.

Salaj P, Kubes R, Cetkovsky P, Capova I, Penka M, Ovesna P, Mesterton J och Lindgren P. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. Thromb Res. 2014 Feb;133(2):162-7.

Piscitelli P, Brandi M, Cawston H, Gauthier A, Kanis JA, Compston J, Borgstrom F, Cooper C och McCloskey E. Epidemiological burden of postmenopausal osteoporosis in Italy from 2010 to 2020: estimations from a disease model. Calcif Tissue Int. 2014 Nov;95(5):419-27.

Mesterton J, Hallberg S, Gandra SR, Banefelt J, Fox KM, Johansson G, Levin LA och Sobocki P. Ldl-C Goal Attainment In Patients With Hyperlipidemia – Estimates From Population-Based Register Data In Sweden. Value Health. 2014 Nov;17(7):A497.

Jonsson E, Cheng LI, Strom O, Intorcia M och Karlsson L. Systematic Review and Meta-Analysis of Persistence With Denosumab in Patients With Osteoporosis. Value Health. 2014 Nov;17(7):A383-4.

Johnsen LG, Hellum C, Storheim K, Nygaard OP, Brox JI, Rossvoll I, Ro M, Andresen H, Lydersen S, Grundnes O, Pedersen M, Leivseth G, Olafsson G, Borgstrom F och Fritzell P. Cost-effectiveness of total disc replacement versus multidisciplinary rehabilitation in patients with chronic low back pain: a Norwegian multicenter RCT. Spine (Phila Pa 1976). 2014 Jan 1;39(1):23-32.

Hubschle L, Borgstrom F, Olafsson G, Roder C, Moulin P, Popp AW, Kulling F och Aghayev E. Real-life results of balloon kyphoplasty for vertebral compression fractures from the SWISSspine registry. Spine J. 2014 Sep 1;14(9):2063-77.

Hallberg S, Banefelt J, Mesterton J, Gandra SR, Fox KM, Johansson G, Levin LA och Sobocki P. Health Care Costs Associated With Cardiovascular Events In Patients With Hyperlipidemia – Estimates From Population-Based Register Data In Sweden. Value Health. 2014 Nov;17(7):A492.

Hallberg S, Banefelt J, Fox KM, Mesterton J, Johansson G, Levin LA, Sobocki P och Gandra SR. Treatment Patterns in Hyperlipidemia Patients With New Cardiovascular Events – Estimates From Population-Based Register Data in Sweden. Value Health. 2014 Nov;17(7):A501.

Dimai HP, Svedbom A, Fahrleitner-Pammer A, Resch H, Muschitz C, Thaler H, Szivak M, Amrein K och Borgstrom F. Epidemiology of distal forearm fractures in Austria between 1989 and 2010. Osteoporos Int. 2014 Sep;25(9):2297-306.

Crous-Bou M, Fung TT, Prescott J, Julin B, Du M, Sun Q, Rexrode KM, Hu FB och De Vivo I. Mediterranean diet and telomere length in Nurses’ Health Study: population based cohort study. Bmj. 2014;349:g6674.

Banefelt J, Liede A, Mesterton J, Stalhammar J, Hernandez RK, Sobocki P och Persson BE. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden. Cancer Epidemiol. 2014 Aug;38(4):442-7.

Banefelt J, Hallberg S, Gandra SR, Mesterton J, Fox KM, Paoli CJ, Johansson G, Levin LA och Sobocki P. Burden Of Hyperlipidemia Resulting From Productivity Loss – Estimates From Population-Based Register Data In Sweden. Value Health. 2014 Nov;17(7):A491-2.

Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, Levin LA, Sobocki P och Gandra SR. Work Productivity Loss and Indirect Costs Associated with New Cardiovascular Events in High-Risk Patients with Hyperlipidemia – Estimates from Population-Based Register Data in Sweden. Value Health. 2014 Nov;17(7):A327-8.

Banefelt J, Gustavsson A, Borgstrom F och Alemao E. Characterizing Work Productivity Loss In Incident Rheumatoid Arthritis In Sweden. Value Health. 2014 Nov;17(7):A383.

Svedbom A, Alvares L, Cooper C, Marsh D och Strom O. Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis. Osteoporos Int. 2013 Jan;24(1):355-67.

Strom O, Jonsson B och Kanis JA. Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int. 2013 Apr;24(4):1491-502.

Lekander I , Kobelt G, Svarvar P, Ljung T, van Vollenhoven R och Borgstrom F. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach. Value Health. 2013 Mar-Apr;16(2):251-8.

Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R och Stenmark J. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos. 2013;8:144.

Julin B, Wolk A, Thomas LD och Akesson A. Exposure to cadmium from food and risk of cardiovascular disease in men: a population-based prospective cohort study. Eur J Epidemiol. 2013 Oct;28(10):837-40.

Julin B, Bergkvist C, Wolk A och Akesson A. Cadmium in diet and risk of cardiovascular disease in women. Epidemiology. 2013 Nov;24(6):880-5.

Iderberg H, Rylander D, Bimpisidis Z och Cenci MA. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp Neurol. 2013 Dec;250:116-24.

Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E, Thaler H, Szivak M, Amrein K och Borgstrom F. Epidemiology of proximal humeral fractures in Austria between 1989 and 2008. Osteoporos Int. 2013 Sep;24(9):2413-21.

Borgstrom F, Olafsson G, Strom O, Tillman JB, Wardlaw D, Boonen S och Miltenburger C. The impact of different health dimensions on overall quality of life related to kyphoplasty and non-surgical management. Osteoporos Int. 2013 Jul;24(7):1991-9.

Borgstrom F, Lekander I , Ivergard M, Strom O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lesnyak O, McCloskey E, Nassonov E, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson AN, Jonsson B och Kanis JA. The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)–quality of life during the first 4 months after fracture. Osteoporos Int. 2013 Mar;24(3):811-23.

Strom O och Landfeldt E. The association between automatic generic substitution and treatment persistence with oral bisphosphonates. Osteoporos Int. 2012 Aug;23(8):2201-9.

Salaj P, Penka M, Smejkal P, Geierova V, Ovesna P, Brabec P, Cetkovsky P, Kubes R, Mesterton J och Lindgren P. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic. Thromb Res. 2012 May;129(5):e233-7.

Rolfson O, Strom O, Karrholm J, Malchau H och Garellick G. Costs related to hip disease in patients eligible for total hip arthroplasty. J Arthroplasty. 2012 Aug;27(7):1261-6.

Lippuner K, Johansson H, Borgstrom F, Kanis JA och Rizzoli R. Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int. 2012 Nov;23(11):2579-89.

Lekander I , Borgstrom F, Lysholm J, van Vollenhoven RF, Lindblad S, Geborek P och Kobelt G. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ. 2012 Sep 19.

Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, Cooper C, Perez AD, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA och Compston JE. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2012;7:25-30.

Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA och Compston JE. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep;23(9):2257-76.

Landfeldt E, Strom O, Robbins S och Borgstrom F. Adherence to treatment of primary osteoporosis and its association to fractures–the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012 Feb;23(2):433-43.

Landfeldt E och Strom O. The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis. Bone. 2012 Oct;51(4):637-42.

Landfeldt E, Jablonowska B, Norlander E, Persdotter-Eberg K, Thurin-Kjellberg A, Wramsby M och Strom O. Patient preferences for characteristics differentiating ovarian stimulation treatments. Hum Reprod. 2012 Mar;27(3):760-9.

Julin B, Wolk A, Johansson JE, Andersson SO, Andren O och Akesson A. Dietary cadmium exposure and prostate cancer incidence: a population-based prospective cohort study. Br J Cancer. 2012 Aug 21;107(5):895-900.

Julin B, Wolk A, Bergkvist L, Bottai M och Akesson A. Dietary cadmium exposure and risk of postmenopausal breast cancer: a population-based prospective cohort study. Cancer Res. 2012 Mar 15;72(6):1459-66.

Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A och Kanis JA. Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2012 Jul;23(7):2063-5.

Iderberg H, Francardo V och Pioli EY. Animal models of L-DOPA-induced dyskinesia: an update on the current options. Neuroscience. 2012 Jun 1;211:13-27.

Gauthier A, Kanis JA, Jiang Y, Dreinhofer K, Martin M, Compston J, Borgstrom F, Cooper C och McCloskey E. Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. Arch Osteoporos. 2012;7:209-18.

Engstrom A, Michaelsson K, Vahter M, Julin B, Wolk A och Akesson A. Associations between dietary cadmium exposure and bone mineral density and risk of osteoporosis and fractures among women. Bone. 2012 Jun;50(6):1372-8.

Dimai HP, Redlich K, Peretz M, Borgstrom F, Siebert U och Mahlich J. Economic burden of osteoporotic fractures in Austria. Health Econ Rev. 2012;2(1):12.

Cawston H, Maravic M, Fardellone P, Gauthier A, Kanis JA, Compston J, Borgstrom F, Cooper C och McCloskey E. Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Arch Osteoporos. 2012;7:237-46.

Thomas LD, Michaelsson K, Julin B, Wolk A och Akesson A. Dietary cadmium exposure and fracture incidence among men: a population-based prospective cohort study. J Bone Miner Res. 2011 Jul;26(7):1601-8.

Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV och Jonsson B. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011;6:59-155.

Lindgren HS, Rylander D, Iderberg H, Andersson M, O’Sullivan SS, Williams DR, Lees AJ och Cenci MA. Putaminal upregulation of FosB/DeltaFosB-like immunoreactivity in Parkinson’s disease patients with dyskinesia. J Parkinsons Dis. 2011;1(4):347-57.

Landfeldt E, Lundkvist J och Strom O. The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone. 2011 Feb;48(2):380-8.

Landfeldt E, Lang A, Robbins S och Strom O. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA). Calcif Tissue Int. 2011 Sep;89(3):234-45.

Kobelt G, Lekander I , Lang A, Raffeiner B, Botsios C och Geborek P. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011 Jul;27(3):193-200.

Julin B, Wolk A och Akesson A. Dietary cadmium exposure and risk of epithelial ovarian cancer in a prospective cohort of Swedish women. Br J Cancer. 2011 Jul 26;105(3):441-4.

Julin B, Vahter M, Amzal B, Wolk A, Berglund M och Akesson A. Relation between dietary cadmium intake and biomarkers of cadmium exposure in premenopausal women accounting for body iron stores. Environ Health. 2011;10:105.

Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A och Kanis JA. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011 Mar;22(3):967-82.

Johansson H, Kanis JA, Ljunggren O, Strom O, Svensson O och Mellstrom D. [FRAX–model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines]. Lakartidningen. 2011 Feb 16-22;108(7):336-9.

Gauthier A, Kanis JA, Martin M, Compston J, Borgstrom F, Cooper C och McCloskey E. Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int. 2011 Mar;22(3):771-80.

Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgstrom F, Cooper C och McCloskey EV. Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos. 2011;6:179-88.

Fritzell P, Ohlin A och Borgstrom F. Cost-effectiveness of balloon kyphoplasty versus standard medical treatment in patients with osteoporotic vertebral compression fracture: a Swedish multicenter randomized controlled trial with 2-year follow-up. Spine (Phila Pa 1976). 2011 Dec 15;36(26):2243-51.

Fritzell P, Berg S, Borgstrom F, Tullberg T och Tropp H. Cost effectiveness of disc prosthesis versus lumbar fusion in patients with chronic low back pain: randomized controlled trial with 2-year follow-up. Eur Spine J. 2011 Jul;20(7):1001-11.

Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E, Chandran M och Borgstrom F. Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int. 2011 Feb;22(2):685-92.

Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Oden A och Kanis JA. Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int. 2011 Mar;22(3):955-65.

Strom O, Leonard C, Marsh D och Cooper C. Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting. Osteoporos Int. 2010 Sep;21(9):1599-608.

Strom O, Borgstrom F, Kleman M, McCloskey E, Oden A, Johansson H och Kanis JA. FRAX and its applications in health economics–cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone. 2010 Aug;47(2):430-7.

Seeman E, Boonen S, Borgstrom F, Vellas B, Aquino JP, Semler J, Benhamou CL, Kaufman JM och Reginster JY. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone. 2010 Apr;46(4):1038-42.

Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E och Cenci MA. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis. 2010 Sep;39(3):352-61.

Moreno S, Gonzalez J, Lekander I , Marti B, Oyaguez I, Sanchez-de la Rosa R och Casado MA. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clin Ther. 2010 Dec;32(13):2232-45.

Mesterton J, Wimo A, By A, Langworth S, Winblad B och Jonsson L. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res. 2010 Jun;7(4):358-67.

Lekander I , Borgstrom F, Svarvar P, Ljung T, Carli C och van Vollenhoven RF. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care. 2010 Jan;26(1):54-61.

Kavakli K, Yesilipek A, Antmen B, Aksu S, Balkan C, Yilmaz D, Kupesiz A, Sasmaz I, Lindgren P och Mesterton J. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010 May;16(3):487-94.

Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O och Borgstrom F. Development and use of FRAX in osteoporosis. Osteoporos Int. 2010 Jun;21 Suppl 2:S407-13.

Ivergard M, Strom O, Borgstrom F, Burge RT, Tosteson AN och Kanis J. Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone. 2010 Nov;47(5):966-74.

Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E, Chandran M och Borgstrom F. Reversal in the secular trend of hip fracture incidences in Austria. Wien Klin Wochenschr. 2010 Jun;122(11-12):380-1.

Borgstrom F, Strom O, Marin F, Kutahov A och Ljunggren O. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis. J Med Econ. 2010;13(3):381-92.

Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV och Kanis JA. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int. 2010 Mar;21(3):495-505.

Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E och Kanis JA. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int. 2010 Feb;21(2):339-49.

Wallin G, Nervall M, Carlsson J och Aqvist J. Charges for Large Scale Binding Free Energy Calculations with the Linear Interaction Energy Method. J Chem Theory Comput. 2009 Feb 10;5(2):380-95.

Strom O, Borgstrom F, Kanis JA och Jonsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int. 2009 Jan;20(1):23-34.

Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM och Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009 Feb;122(2 Suppl):S3-13.

Mesterton J, Jonsson L, Almer SH, Befrits R, Friis-Liby I och Lindgren S. Resource use and societal costs for Crohn’s disease in Sweden. Inflamm Bowel Dis. 2009 Dec;15(12):1882-90.

Lekander I , Borgstrom F, Strom O, Zethraeus N och Kanis JA. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. Menopause Int. 2009 Mar;15(1):19-25.

Lekander I , Borgstrom F, Strom O, Zethraeus N och Kanis JA. Cost-effectiveness of hormone therapy in the United States. J Womens Health (Larchmt). 2009 Oct;18(10):1669-77.

Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O och McCloskey E. FRAX and its applications to clinical practice. Bone. 2009 May;44(5):734-43.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F och Oden A. How to decide who to treat. Best Pract Res Clin Rheumatol. 2009 Dec;23(6):711-26.

Amzal B, Julin B, Vahter M, Wolk A, Johanson G och Akesson A. Population toxicokinetic modeling of cadmium for health risk assessment. Environ Health Perspect. 2009 Aug;117(8):1293-301.

Zethraeus N, Strom O, Borgstrom F, Kanis JA och Jonsson B. The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. Osteoporos Int. 2008 Jun;19(6):819-27.

Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I och Jonsson B. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop. 2008 Apr;79(2):269-80.

Nervall M, Hanspers P, Carlsson J, Boukharta L och Aqvist J. Predicting binding modes from free energy calculations. J Med Chem. 2008 May 8;51(9):2657-67.

Lekander I , Borgstrom F, Strom O, Zethraeus N och Kanis JA. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK-Results based on the Women’s Health Initiative randomised controlled trial. Bone. 2008 Feb;42(2):294-306.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F och Oden A. Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int. 2008 Oct;19(10):1395-408.

Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F och Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008 Apr;19(4):399-428.

Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P och Compston J. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008 Jan;42(1):4-15.

Jager M, Lekander I , Sobocki P, Schwab ME och Rossler W. Resource allocation to brain research in Switzerland. Swiss Med Wkly. 2008 Jun 14;138(23-24):335-9.

Borgstrom F och Kanis JA. Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):885-900.

Akesson A, Julin B och Wolk A. Long-term dietary cadmium intake and postmenopausal endometrial cancer incidence: a population-based prospective cohort study. Cancer Res. 2008 Aug 1;68(15):6435-41.

Zethraeus N, Borgstrom F, Strom O, Kanis JA och Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis–a review of the literature and a reference model. Osteoporos Int. 2007 Jan;18(1):9-23.

Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O och Kanis JA. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries–an economic evaluation based on the fracture intervention trial. Osteoporos Int. 2007 Aug;18(8):1047-61.

Sobocki P, Lekander I , Borgstrom F, Strom O och Runeson B. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry. 2007 Apr;22(3):146-52.

Olesen J, Lekander I och Sobocki P. Resource allocation to brain research in Denmark: an example for other European countries. Eur J Neurol. 2007 Jun;14(6):667-71.

Olesen J, Lekander I , Andlin-Sobocki P och Jonsson B. Funding of headache research in Europe. Cephalalgia. 2007 Sep;27(9):995-9.

Lindgren P, Borgstrom F, Stalhammar J, Alemao E och Jonsson L. Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. Int J Clin Pract. 2007 Aug;61(8):1410-4.

Johnell O, Borgstrom F, Jonsson B och Kanis J. Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int. 2007 Mar;18(3):333-7.

Borgstrom F, Sobocki P, Strom O och Jonsson B. The societal burden of osteoporosis in Sweden. Bone. 2007 Jun;40(6):1602-9.

Bjelic S, Nervall M, Gutierrez-de-Teran H, Ersmark K, Hallberg A och Aqvist J. Computational inhibitor design against malaria plasmepsins. Cell Mol Life Sci. 2007 Sep;64(17):2285-305.

Sobocki P, Lekander I , Berwick S, Olesen J och Jonsson B. Resource allocation to brain research in Europe (RABRE). Eur J Neurosci. 2006 Nov;24(10):2691-3.

Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgstrom F och Jonsson L. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs. 2006;6(2):121-8.

Luzhkov VB, Almlof M, Nervall M och Aqvist J. Computational study of the binding affinity and selectivity of the bacterial ammonium transporter AmtB. Biochemistry. 2006 Sep 12;45(36):10807-14.

Lovmar M, Nilsson K, Vimberg V, Tenson T, Nervall M och Ehrenberg M. The molecular mechanism of peptide-mediated erythromycin resistance. J Biol Chem. 2006 Mar 10;281(10):6742-50.

Gutierrez-de-Teran H, Nervall M, Ersmark K, Liu P, Janka LK, Dunn B, Hallberg A och Aqvist J. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum. Biochemistry. 2006 Sep 5;45(35):10529-41.

Gutierrez-de-Teran H, Nervall M, Dunn BM, Clemente JC och Aqvist J. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor. FEBS Lett. 2006 Oct 30;580(25):5910-6.

Ersmark K, Nervall M, Gutierrez-de-Teran H, Hamelink E, Janka LK, Clemente JC, Dunn BM, Gogoll A, Samuelsson B, Qvist J och Hallberg A. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg Med Chem. 2006 Apr 1;14(7):2197-208.

Carlsson J, Ander M, Nervall M och Aqvist J. Continuum solvation models in the linear interaction energy method. J Phys Chem B. 2006 Jun 22;110(24):12034-41.

Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C och Jonsson B. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int. 2006;17(5):637-50.

Borgstrom F, Jonsson B, Strom O och Kanis JA. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int. 2006 Dec;17(12):1781-93.

Borgstrom F, Johnell O, Kanis JA, Jonsson B och Rehnberg C. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int. 2006 Oct;17(10):1459-71.

Borgstrom F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jonsson B och Kanis JA. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int. 2006;17(7):996-1007.

Borgstrom F. [Osteoporosis in health economic perspective]. Lakartidningen. 2006 Oct 4-10;103(40):2963-5.

Zethraeus N, Borgstrom F, Jonsson B och Kanis J. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial. Int J Technol Assess Health Care. 2005 Fall;21(4):433-41.

Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Yin DD och Jonsson L. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil. 2005 Dec;12(6):530-4.

Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C och Jonsson B. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int. 2005 Jan;16(1):6-14.

Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A och Jonsson B. Intervention thresholds for osteoporosis in the UK. Bone. 2005 Jan;36(1):22-32.

Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D och Jonsson B. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int. 2005 Jan;16(1):15-25.

Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B och Khaltaev N. Assessment of fracture risk. Osteoporos Int. 2005 Jun;16(6):581-9.

Ersmark K, Nervall M, Hamelink E, Janka LK, Clemente JC, Dunn BM, Blackman MJ, Samuelsson B, Aqvist J och Hallberg A. Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J Med Chem. 2005 Sep 22;48(19):6090-106.

Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C och Jonsson B. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004 Jan;15(1):20-6.

Kanis JA, Borgstrom F, Johnell O och Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int. 2004 Nov;15(11):862-71.

Carlsson A, Borgstrom F, Stalhammar J, Alemao E, Yin D och Jonsson L. Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics. 2004;22 Suppl 3:25-35.

Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D och Jonsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics. 2004;22(17):1153-65.

Borgstrom F, Johnell O, Jonsson B, Zethraeus N och Sen SS. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone. 2004 Jun;34(6):1064-71.

Kobelt G, Borgstrom F och Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int. 2003 Feb;91(3):190-5.

Jonsson L, Borgstrom F och Zethraeus N. [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial]. Ugeskr Laeger. 2003 Oct 20;165(43):4112-6.

Borgstrom F och Zethraeus N. [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective]. Lakartidningen. 2003 Jan 9;100(1-2):36-40.